Will Delays in Treatment Jeopardize the Population Benefit From Extending the Time Window for Stroke Thrombolysis?
- 1 November 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 43 (11), 2992-2997
- https://doi.org/10.1161/strokeaha.111.638650
Abstract
Background and Purpose— Pooled analyses show benefits of intravenous alteplase (recombinant tissue-type plasminogen activator) treatment for acute ischemic stroke up to 4.5 hours after onset despite marketing approval for up to 3 hours. However, the benefit from thrombolysis is critically time-dependent and if extending the time window reduces treatment urgency, this could reduce the population benefit from any extension. Methods— Based on 3830 UK patients registered between 2005 to 2010 in the Safe Implementation of Treatments in Stroke–International Stroke Thrombolysis Registry (SITS-ISTR), a Monte Carlo simulation was used to model recombinant tissue-type plasminogen activator treatment up to 4·5 hours from onset and assess the impact (numbers surviving with little or no disability) from changes in hospital treatment times associated with this extended time window. Results— We observed a significant relation between time remaining to treat and time taken to treat in the UK SITS-ISTR data set after adjustment for censoring. Simulation showed that as this “deadline effect” increases, an extended treatment time window entails that an increasing number of patients are treated at a progressively lower absolute benefit to a point where the population benefit from extending the time window is entirely negated. Conclusions— Despite the benefit for individual patients treated up to 4.5 hours after onset, the population benefit may be reduced or lost altogether if extending the time window results in more patients being treated but at a lower absolute benefit. A universally applied reduction in hospital arrival to treatment times of 8 minutes would confer a population benefit as large as the time window extension.Keywords
This publication has 16 references indexed in Scilit:
- Stroke Thrombolysis: Having More Time Translates Into Delayed TherapyStroke, 2010
- A Computerized In-Hospital Alert System for Thrombolysis in Acute StrokeStroke, 2010
- Implementation and outcome of thrombolysis with alteplase 3–4·5 h after an acute stroke: an updated analysis from SITS-ISTRThe Lancet Neurology, 2010
- The “Golden Hour” and Acute Brain IschemiaStroke, 2010
- Alteplase for ischaemic stroke—much sooner is much betterThe Lancet, 2010
- Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trialsThe Lancet, 2010
- Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen ActivatorStroke, 2009
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- Thrombolytic Therapy for Acute Stroke — Not a Moment to LoseNew England Journal of Medicine, 2008
- In-hospital delays to stroke thrombolysis: paradoxical effect of early arrivalNeurological Research, 2007